Sacral neuromodulation in the management of chronic pelvic pain: A systematic review and meta‐analysis

Author:

Greig Julian1ORCID,Mak Quentin1ORCID,Furrer Marc A.23ORCID,Sahai Arun2ORCID,Raison Nicholas24ORCID

Affiliation:

1. Faculty of Life Sciences and Medicine King's College London London UK

2. Department of Urology Guy's and St Thomas' NHS Foundation Trust London UK

3. Department of Urology University of Bern Bern Switzerland

4. MRC Centre for Transplantation, Guy's Hospital King's College London London UK

Abstract

AbstractIntroductionSacral neuromodulation (SNM) is a treatment approved for use in several conditions including refractory overactive bladder (OAB) and voiding dysfunction. Chronic pelvic pain (CPP) is a debilitating condition for which treatment is often challenging. SNM shows promising effect in patients with refractory CPP. However, there is a lack of clear evidence, especially in long‐term outcomes. This systematic review will assess outcomes of SNM for treating CPP.MethodsA systematic search of MEDLINE, Embase, Cochrane Central and clinical trial databases was completed from database inception until January 14, 2022. Studies using original data investigating SNM in an adult population with CPP which recorded pre and posttreatment pain scores were selected. Primary outcome was numerical change in pain score. Secondary outcomes were quality of life assessment and change in medication use and all‐time complications of SNM. Risk of bias was assessed using the Newcastle Ottawa Tool for cohort studies.ResultsTwenty‐six of 1026 identified articles were selected evaluating 853 patients with CPP. The implantation rate after test‐phase success was 64.3%. Significant improvement of pain scores was reported in 13 studies; three studies reported no significant change. WMD in pain scores on a 10‐point scale was −4.64 (95% confidence interval [CI] = −5.32 to −3.95, p < 0.00001) across 20 studies which were quantitatively synthesized: effects were maintained at long‐term follow‐up. Mean follow‐up was 42.5 months (0–59). Quality of life was measured by RAND SF‐36 and EQ‐5D questionnaires and all studies reported improvement in quality of life. One hundred and eighty‐nine complications were reported in 1555 patients (Clavien‐Dindo Grade I‐IIIb). Risk of bias ranged from low to high risk. Studies were case series and bias stemmed from selection bias and loss to follow‐up.ConclusionSacral Neuromodulation is a reasonably effective treatment of Chronic Pelvic Pain and significantly reduces pain and increases patients’ quality of life with immediate to long‐term effects.

Publisher

Wiley

Subject

Urology,Neurology (clinical)

Reference47 articles.

1. Royal College of Obstetricians and Gynaecologists.Initial Management of Chronic Pelvic Pain (Green‐top Guideline No. 41);2012.https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_41.pdf

2. The community prevalence of chronic pelvic pain in women and associated illness behaviour;Zondervan KT;Br J Gen Pract,2001

3. Psychology of Chronic Pelvic Pain: Prevalence, Neurobiological Vulnerabilities, and Treatment

4. European Association of Urology.Guidelines on Chronic Pelvic Pain. European Association of Urology;2015.

5. Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3